Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Calabresi

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Neurology|October 27, 1997
VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon betaP A Calabresi, C M Pelfrey, L R Tranquill, et al.
Neurology|November 28, 2007
Optical coherence tomography and disease subtype in multiple sclerosisM Pulicken, E Gordon-Lipkin, L J Balcer, et al.
Neurology|May 1, 1997
Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRIP A Calabresi, L A Stone, C N Bash, et al.
Neurology|January 24, 2002
An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MSP A Calabresi, J L Wilterdink, J M Rogg, et al.
Neurology|May 9, 2007
Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamideB M Greenberg, K P Thomas, C Krishnan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 1996
MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapiesH F McFarland, L A Stone, P A Calabresi, et al.
Neurology|December 11, 2002
Impaired renal function in progressive multiple sclerosisP A Calabresi, H Austin, M K Racke, et al.
AJNR. American Journal of Neuroradiology|March 5, 2016
Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis SeverityD M Harrison, X Li, H Liu, et al.
Pharmacology & Therapeutics|April 1, 1995
Gene-modified cells for the treatment of cancerK A Whartenby, G N Abraham, P A Calabresi, et al.
Annals of Neurology|February 5, 1998
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosisF Zipp, M Weller, P A Calabresi, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Neurology|October 27, 1997
VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon betaP A Calabresi, C M Pelfrey, L R Tranquill, et al.
Neurology|November 28, 2007
Optical coherence tomography and disease subtype in multiple sclerosisM Pulicken, E Gordon-Lipkin, L J Balcer, et al.
Neurology|May 1, 1997
Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRIP A Calabresi, L A Stone, C N Bash, et al.
Neurology|January 24, 2002
An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MSP A Calabresi, J L Wilterdink, J M Rogg, et al.
Neurology|May 9, 2007
Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamideB M Greenberg, K P Thomas, C Krishnan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 1996
MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapiesH F McFarland, L A Stone, P A Calabresi, et al.
Neurology|December 11, 2002
Impaired renal function in progressive multiple sclerosisP A Calabresi, H Austin, M K Racke, et al.
AJNR. American Journal of Neuroradiology|March 5, 2016
Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis SeverityD M Harrison, X Li, H Liu, et al.
Pharmacology & Therapeutics|April 1, 1995
Gene-modified cells for the treatment of cancerK A Whartenby, G N Abraham, P A Calabresi, et al.
Annals of Neurology|February 5, 1998
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosisF Zipp, M Weller, P A Calabresi, et al.
Pageof 6